LIFECORE BIOMEDICAL, INC. \DE\ — Form SCHEDULE 13D/A
Filed September 28, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Legion Partners Asset Management, LLC filed an amended Schedule 13D/A regarding LifeCore Biomedical, Inc. (DE) on September 28, 2026. The filing document itself does not contain specific details about share count, percentage ownership, dollar amounts, or what changed from the original filing—only that this is an amendment to a prior 13D. The actual substantive disclosures are in the linked documents, which are not fully rendered in this text extract.
Why this rating
Amendment to existing 13D filing; no concrete new facts disclosed here. Cannot assess materiality without knowing stakes/changes. Routine disclosure update.
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.